Your browser doesn't support javascript.
loading
Prostate-Specific Antigen: Nonspecific in Deceased Organ Donors.
Pabisiak, K; Ostrowski, M; Kram, A; Safranow, K; Myslak, M; Sienko, J; Sulikowski, T; Ciechanowski, K.
Afiliación
  • Pabisiak K; Department of Nephrology Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland; Polish Transplant Coordinating Center-Poltransplant, Warsaw, Poland. Electronic address: bkpn@pum.edu.pl.
  • Ostrowski M; Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Kram A; West Pomeranian Oncology Center, Szczecin, Poland.
  • Safranow K; Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland.
  • Myslak M; Department of Nephrology Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.
  • Sienko J; Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Sulikowski T; Department of General Surgery and Transplantation, Pomeranian Medical University, Szczecin, Poland.
  • Ciechanowski K; Department of Nephrology Transplantation and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.
Transplant Proc ; 48(5): 1374-7, 2016 Jun.
Article en En | MEDLINE | ID: mdl-27496408
ABSTRACT
Currently, there is no clear position regarding the donation of organs from donors with prostate carcinoma (CaP) in European countries, except Italy. The lengthening of life expectancy increases the probability of prostate cancer among potential organ donors. The concentration of prostate-specific antigen (PSA) >2 ng/mL at 60 years of age is related to the increasing possibility of identifying an advanced form of CaP. In recent years in Poland, the recommendation has been to determine tumor markers in potential donors. In the first year of the recommendation, 10% of potential male cadaveric donors were disqualified in West Pomerania, Poland, on the basis of elevated PSA levels (>10 ng/mL). To avoid reduction of the actual donor pool, each potential male donor reported to the center since January 2010 undergoes a routine histologic evaluation of the whole prostate, regardless of the PSA level, before organ implantation. In the study group (N = 52), histopathologic evaluation revealed 6 cases of CaP (12%). In CaP positive group Gleason score range from 2+2 to 3+4. In CaP donors PSA level have been noticed in range 1.79 ng/mL - 7.66 ng/mL. There was no correlation between histologically confirmed CaP and the PSA level.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Neoplasias de la Próstata / Donantes de Tejidos / Carcinoma / Biomarcadores de Tumor / Antígeno Prostático Específico / Neoplasia Intraepitelial Prostática / Selección de Donante Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies País/Región como asunto: Europa Idioma: En Revista: Transplant Proc Año: 2016 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Hiperplasia Prostática / Neoplasias de la Próstata / Donantes de Tejidos / Carcinoma / Biomarcadores de Tumor / Antígeno Prostático Específico / Neoplasia Intraepitelial Prostática / Selección de Donante Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies País/Región como asunto: Europa Idioma: En Revista: Transplant Proc Año: 2016 Tipo del documento: Article